Key Stats for Philip Morris Stock
- Past-Week Performance: +2.8%
- 52-Week Range: $142.1 to $191.3
- Current Price: $174.8
What Happened?
Philip Morris (PM), the global tobacco and nicotine giant executing one of consumer staples’ most credible smoke-free transformations, crossed a structural milestone in 2025 as smoke-free products generated $17 billion in revenue, now 41.5% of total net revenues, with shares trading near $176.
The February 6 Q4 earnings call confirmed the trigger: adjusted diluted EPS of $7.54 for full-year 2025, up 15% in dollar terms and the strongest growth since 2011, while ZYN, PMI’s oral nicotine pouch brand that competes directly in the fastest-growing U.S. nicotine segment, shipped 794 million cans, up 37%.
ZYN held 61.5% U.S. can volume share and over 67% value share even as rival Velo, British American Tobacco’s competing pouch brand, claimed the number-two position, underscoring that category leadership is widening in dollar terms faster than unit terms.
Just today, Philip Morris announced a $50 million, 10-year investment in a Tampa Business Solutions Center expected to create 180 jobs across finance, data engineering, and technology, a concrete operational commitment that signals the infrastructure buildout supporting the company’s accelerating U.S. smoke-free expansion.
Furthermore, CFO Emmanuel Babeau stated on the Q4 2025 earnings call that “we’ve been passing 40% OI margin,” and management targets $45 billion in aggregate operating cash flow through 2028 alongside a leverage ratio approaching 2x, as pending FDA action on ZYN Ultra, a higher-strength pouch product, and a potential IQOS ILUMA U.S. launch position PMI for a second leg of domestic smoke-free growth.
Wall Street’s Take on PM Stock
PMI’s smoke-free mix shift, which drove smoke-free products to 41.5% of revenues in 2025, directly supports TIKR’s projection of $8.44 normalized EPS in 2026, up 11.9% from $7.54, as higher-margin ZYN pouches and IQOS heat-not-burn devices displace lower-margin cigarette volume.
TIKR estimates revenue reaching $43.7 billion in 2026 and $46.7 billion in 2027, backed by PMI’s own guidance of 5%–7% organic net revenue growth and a smoke-free portfolio generating 2.5x more gross profit per unit than combustibles.
British American Tobacco (BAT), PMI’s closest global tobacco peer, posted normalized EPS of $3.52 in 2025 growing just 1.9% to a projected $3.59 in 2026, against PMI’s 11.9% projected EPS growth, a gap that reflects PMI’s structurally superior smoke-free mix and U.S. ZYN dominance.
Eight analysts rate PM a Buy, five an Outperform, four a Hold, and one an Underperform, producing a mean price target of $194.84 against a current price near $174.78, implying 11.5% upside as Wall Street prices in ZYN’s continued category leadership and IQOS international momentum.
The spread between the Street’s $170 low target and $210 high target reflects a binary read on FDA timing: the low anchors to a scenario where ZYN Ultra authorization stalls and Japan excise headwinds compound, while the high prices in a 2026 ZYN Ultra launch and accelerating U.S. smoke-free penetration.
What Does the Valuation Model Say?
TIKR’s $239.99 mid-case target implies 37.3% total return over 4.8 years at a 6.8% annualized IRR, pricing in a 6.3% revenue CAGR and net income margins expanding from 28.9% to 31.1%, assumptions grounded in PMI’s own $45 billion operating cash flow target through 2028 and $2 billion in cumulative gross cost savings by end of 2026.
The market prices PM at roughly 20.7x 2026 estimated EPS of $8.44, but that multiple does not reflect a business where smoke-free gross profit has doubled as a share of total in five years to 43%.
TIKR’s $239.99 mid-case target rests on ZYN’s U.S. dominance holding at 61.5% can volume share and IQOS international adjusted in-market sales sustaining high-single-digit growth, both of which management confirmed as operational baselines on the February 6 earnings call.
Management’s commitment to a 10-year Tampa facility lease and $50 million U.S. infrastructure investment, announced March 17, signals that the domestic smoke-free buildout is a multi-year capital commitment, not a one-cycle trade.
Japan’s two-step excise tax increases in April and October 2026, estimated to represent 20% of current retail prices, remain the single development that most directly threatens TIKR’s high-single-digit smoke-free volume growth assumption and could compress the 2026 organic operating income floor of 7%.
Q1 2026 earnings, where management guided broadly flat organic net revenue and operating income year-on-year, will confirm whether ZYN’s 25-million-can surplus inventory has cleared the downstream supply chain and whether the $1.80–$1.85 EPS guidance range is tracking on schedule.
Should You Invest in Philip Morris International Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up PM stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Philip Morris International Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze PM stock on TIKR for Free →
